SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14 and conduct a virtual presentation. The virtual presentation will take place on Wednesday, February 14, 2024, at 12:40 pm ET.
A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
This email address is being protected from spambots. You need JavaScript enabled to view it.
Julie Fallon
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$49.96 |
Daily Change: | -0.14 -0.28 |
Daily Volume: | 69,280 |
Market Cap: | US$1.490B |
June 12, 2024 March 22, 2024 March 11, 2024 November 13, 2023 |
Pond Technologies has developed a proprietary system that can profitably transform CO2 into valuable products. The company's carbon business focuses on absorbing greenhouse gas emissions, transforming these into...
CLICK TO LEARN MORELithiumBank Resources is creating an opportunity to participate in the future of clean-tech energy. The company's strategy is to acquire claims in known lithium high grade hot spots with existing wells and infrastructure...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS